Journey Medical (DERM) Competitors $7.10 +0.06 (+0.85%) As of 07/3/2025 01:04 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock DERM vs. KALV, EOLS, SANA, UPB, SAGE, ALT, TNGX, KROS, RLAY, and AUTLShould you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include KalVista Pharmaceuticals (KALV), Evolus (EOLS), Sana Biotechnology (SANA), Upstream Bio (UPB), Sage Therapeutics (SAGE), Altimmune (ALT), Tango Therapeutics (TNGX), Keros Therapeutics (KROS), Relay Therapeutics (RLAY), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Journey Medical vs. Its Competitors KalVista Pharmaceuticals Evolus Sana Biotechnology Upstream Bio Sage Therapeutics Altimmune Tango Therapeutics Keros Therapeutics Relay Therapeutics Autolus Therapeutics KalVista Pharmaceuticals (NASDAQ:KALV) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability. Which has more volatility and risk, KALV or DERM? KalVista Pharmaceuticals has a beta of -0.04, suggesting that its stock price is 104% less volatile than the S&P 500. Comparatively, Journey Medical has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500. Does the media prefer KALV or DERM? In the previous week, KalVista Pharmaceuticals had 4 more articles in the media than Journey Medical. MarketBeat recorded 6 mentions for KalVista Pharmaceuticals and 2 mentions for Journey Medical. KalVista Pharmaceuticals' average media sentiment score of 0.22 beat Journey Medical's score of -0.25 indicating that KalVista Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment KalVista Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Journey Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend KALV or DERM? KalVista Pharmaceuticals currently has a consensus price target of $24.83, suggesting a potential upside of 108.68%. Journey Medical has a consensus price target of $9.50, suggesting a potential upside of 33.80%. Given KalVista Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe KalVista Pharmaceuticals is more favorable than Journey Medical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Journey Medical 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is KALV or DERM more profitable? KalVista Pharmaceuticals has a net margin of 0.00% compared to Journey Medical's net margin of -14.76%. Journey Medical's return on equity of -52.03% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets KalVista PharmaceuticalsN/A -104.25% -78.69% Journey Medical -14.76%-52.03%-11.28% Which has preferable valuation & earnings, KALV or DERM? Journey Medical has higher revenue and earnings than KalVista Pharmaceuticals. Journey Medical is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKalVista PharmaceuticalsN/AN/A-$126.64M-$3.72-3.20Journey Medical$56.13M2.95-$14.67M-$0.39-18.21 Do institutionals and insiders hold more shares of KALV or DERM? 7.3% of Journey Medical shares are held by institutional investors. 10.5% of KalVista Pharmaceuticals shares are held by insiders. Comparatively, 15.0% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryKalVista Pharmaceuticals and Journey Medical tied by winning 8 of the 16 factors compared between the two stocks. Get Journey Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DERM vs. The Competition Export to ExcelMetricJourney MedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$165.40M$2.43B$5.56B$9.05BDividend YieldN/A1.78%5.24%3.99%P/E Ratio-18.219.0227.6520.23Price / Sales2.95680.43419.56119.26Price / CashN/A21.7726.2128.59Price / Book7.804.558.035.65Net Income-$14.67M$31.26M$3.18B$249.15M7 Day Performance-0.56%3.25%2.93%3.28%1 Month Performance-3.92%3.46%1.72%3.95%1 Year Performance36.28%0.77%34.39%20.98% Journey Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DERMJourney Medical1.922 of 5 stars$7.10+0.9%$9.50+33.8%+36.3%$165.40M$56.13M-18.2190Analyst DowngradeKALVKalVista Pharmaceuticals4.1434 of 5 stars$11.93-1.8%$24.83+108.2%+0.9%$604.04MN/A-3.21100Upcoming EarningsEOLSEvolus3.6908 of 5 stars$9.38+1.1%$23.75+153.2%-15.2%$598.33M$266.27M-10.54170Positive NewsSANASana Biotechnology2.7581 of 5 stars$2.60-0.4%$10.80+315.4%-37.2%$588.49MN/A-2.95380Analyst ForecastGap UpHigh Trading VolumeUPBUpstream BioN/A$10.72-1.5%$56.50+427.1%N/A$585.28M$2.37M0.0038SAGESage Therapeutics3.222 of 5 stars$9.30flat$8.93-3.9%-14.7%$582.37M$41.24M-1.60690ALTAltimmune2.2023 of 5 stars$6.99-0.6%$19.00+171.8%-28.1%$570.18M$20K-5.5550TNGXTango Therapeutics1.969 of 5 stars$5.32+3.1%$12.20+129.3%-33.5%$559.31M$42.07M-4.3690Analyst RevisionKROSKeros Therapeutics4.0634 of 5 stars$13.76+2.0%$30.56+122.1%-68.4%$547.90M$3.55M-76.44100RLAYRelay Therapeutics2.7909 of 5 stars$3.23+1.3%$17.67+447.0%-43.1%$546.91M$10.01M-1.45330Positive NewsAUTLAutolus Therapeutics2.5424 of 5 stars$2.21+7.8%$9.32+321.7%-31.3%$545.59M$10.12M-2.51330 Related Companies and Tools Related Companies KalVista Pharmaceuticals Competitors Evolus Competitors Sana Biotechnology Competitors Upstream Bio Competitors Sage Therapeutics Competitors Altimmune Competitors Tango Therapeutics Competitors Keros Therapeutics Competitors Relay Therapeutics Competitors Autolus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DERM) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredFINAL HOURS: $9 Income ETF Access VANISHES at MIDNIGHTTHIS IS IT. Your FINAL CHANCE. At midnight, our 82% OFF July 4th deal disappears FOREVER. The countdown ...Investors Alley | SponsoredGold buying hits 4-year highThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Journey Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Journey Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
